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Abstract
The latent cellular reservoir of HIV is recognized as the major barrier to cure from HIV infec-
tion. Long non-coding RNAs (lncRNAs) are more tissue and cell type-specific than protein
coding genes, and may represent targets of choice for HIV latency reversal. Using two in
vitro primary T-cell models, we identified lncRNAs dysregulated in latency. PVT1 and RP11-
347C18.3 were up-regulated in common between the two models, and RP11-539L10.2 was
down-regulated. The major component of the latent HIV reservoir, memory CD4+ T-cells,
had higher expression of these lncRNAs, compared to naïve T-cells. Guilt-by-association
analysis demonstrated that lncRNAs dysregulated in latency were associated with several
cellular pathways implicated in HIV latency establishment and maintenance: proteasome,
spliceosome, p53 signaling, and mammalian target of rapamycin (MTOR). PVT1, RP11-
347C18.3, and RP11-539L10.2 were down-regulated by latency reversing agents, suberoy-
lanilide hydroxamic acid and Romidepsin, suggesting that modulation of lncRNAs is a possi-
ble secondary mechanism of action of these compounds. These results will facilitate
prioritization of lncRNAs for evaluation as targets for HIV latency reversal. Importantly, our
study provides insights into regulatory function of lncRNA during latent HIV infection.
Introduction
In the present era of combination anti-retroviral therapy (cART), the latent cellular reservoir
of HIV is recognized as the major barrier to a cure [1–3]. Existing latency reversing agents
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(LRAs) are suboptimal to induce a sustained reduction of the latent reservoir in vivo and suffer
from lack of specificity for HIV [4]. Long non-coding RNAs (lncRNAs) may present targets of
choice for HIV latency reversal because they are more tissue and cell-type specific than protein
coding genes [5] and can be accurately targeted by oligonucleotides.
Though the role of individual lncRNAs in regulation of HIV expression and their possible
contribution to HIV latency control has been recognized, the number of lncRNAs that were
studied in this setting is limited. For example, siRNA-mediated knockdown or CRISPR-Ca-
s9-induced knockout of Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) resulted in
enhanced HIV replication and an increase of unspliced and singly-spliced HIV RNA in the
cytoplasmic fraction [6, 7], consistent with a possible role of NEAT1 in HIV RNA nuclear
retention. Although these experiments were performed using productively infected cell lines
[6], the results from this study suggested a possible role for NEAT1 in post-transcriptional reg-
ulation of HIV latency via nuclear retention of HIV transcripts, warranting further investiga-
tion in appropriate model systems. Another example is Non-Protein Coding RNA, Repressor
of NFAT (NRON), whose function in HIV latency control was demonstrated using an in vitro
model of HIV latency and cells from HIV-infected patients receiving cART [8]. NRON pro-
moted HIV latency by recruiting the transactivator protein Tat to the proteasome for degrada-
tion; knockdown of NRON resulted in reactivation of the latent provirus [8]. In addition,
NRON may also regulate HIV replication via cytoplasmic retention of nuclear factor of acti-
vated T-cells (NFAT) [9], which enhances HIV transcription in primary CD4+ T-cells [10]. In
contrast, MALAT1 and uc002yug.2 lncRNAs were shown to be positive regulators of HIV rep-
lication [11, 12]. MALAT1 sequestered polycomb repressive complex 2 from the HIV LTR,
promoting its transcriptionally active state [12]. Uc002yug.2 functioned via up-regulation of
Tat and down-regulation of HIV transcriptional repressors Runx1b and Runx1c; overexpres-
sion of uc002yug.2 in cells from HIV-infected patients on cART improved HIV reactivation
following treatment with phytohemagglutinin M [11]. Because lncRNAs represent a greater
fraction of the transcribed human genome than protein coding genes [13], it is plausible to
hypothesize that there are more lncRNAs than currently demonstrated that participate in regu-
lation of HIV expression and may contribute to HIV latency.
To-date, very few studies have attempted to explore the complexity of host-HIV interac-
tions in the context of lncRNA expression and function. We and others have previously pro-
filed the entire transcriptome, including lncRNAs, at different time points following HIV
infection in the SupT1 cell line [14, 15]. Peng and colleagues demonstrated that early response
to HIV infection included changes in expression of many lncRNA, some of which were inde-
pendent of active HIV replication [15]. We further expanded on this study to explore changes
in lncRNA expression during different stages of the HIV replication cycle, including reverse
transcription, integration and particle production [14]. Guilt-by-association (GBA) analysis
demonstrated that dysregulated lncRNAs were functionally linked to many pathways involved
in regulation of T-cell function and anti-viral responses [14, 15], consistent with the idea that
lncRNAs represent a part of the host response to HIV infection and may be involved in regula-
tion of induced cellular pathways.
To our knowledge, lncRNAs have not been previously profiled during latent HIV infection
in primary CD4+ T cells. In the present study, we sought to identify lncRNA dysregulated in
two relevant primary T-cell models of HIV latency using RNA-Seq. The models that use repli-
cation-competent wild type HIV virus were selected in order to recapitulate more closely the
effects of latency in vivo. Because latency is preferentially established in memory compared to
naïve cells, we further aimed to determine the relationship between expression levels of
lncRNAs dysregulated in latency and CD4+ T-cell maturation state. To infer the function of
dysregulated lncRNA in HIV latency establishment and maintenance, we performed GBA
lncRNA and HIV latency
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analysis that identifies cellular pathways associated with lncRNAs. Finally, we aimed to deter-
mine whether the selected dysregulated lncRNAs are modulated by small molecule LRAs sub-
eroylamilide hydroxamic acid (SAHA) and Romidepsin (RMD), and whether effects of SAHA
and RMD on lncRNA may represent novel secondary mechanisms of action of these com-
pounds with respect to HIV reactivation. The main motivation behind the present study was
prioritization of candidate lncRNAs for further formal evaluation as targets for therapies
aimed at eradication of the latent HIV reservoir.
Results
Models of HIV latency
To identify lncRNAs dysregulated in HIV latency, the cultured TCM [16, 17] and the bystander
model [18, 19] of HIV latency were used. These models differ by the phenotypic composition
of CD4+ T-cells and the route of latency establishment (dividing cells returning to quiescence
or resting cells). Cultured TCM model originally developed by Bosque and Planelles [16, 17] is
established over 17 days of culture, where initial infection is conducted by spinoculation after
7 days following cell activation and expansion. Further virus replication and transmission is
facilitated via cell-to-cell contact during the crowding stage till day 13, when the peak of p24
+ expression is observed (21.8 ± 7.8 percent p24+ cells, N = 4). Virus spread is stopped at this
point by adding antiretrovirals, and cells are allowed to return to quiescence for another 4 days
[20]. Before samples are processed for sequencing, positive magnetic isolation of CD4+ T cells
is used to sort out cells that may be productively infected [21]. Integration events in this model
were characterized previously using Alu-PCR [21] detecting 33 ± 10.6% cells with HIV provi-
rus on day 17, on average (N = 5), assuming 160 cells generate 1 ng DNA. “Bystander” model,
described in [18] and [19], uses a shorter culture period, where a subset of cells is initially
stained with a viable dye, e-Fluor 670, infected with HIV and activated, followed by mixing of
these cells with resting “bystander” cells. Resting bystander cells are represented by all major
phenotypic subsets found in vivo, including naïve, central memory and effector memory cells.
Virus transmission from infected proliferating to bystander cells occurs in this co-culture via
cell-to-cell contact. Peak of infection (average 37.3 ± 10.4 percent of p24+ proliferating cells,
N = 4) is achieved on day 7. At this point, the resting (e-Fluor 670 negative) bystander cells are
sorted out from the co-culture by fluorescence activated cell sorting. Following separation
from productively infected cells, resting cells are left in culture for another 3 days to complete
integration events of virus that entered the cells. Integration events in the end of culture were
evaluated previously by droplet digital PCR (ddPCR) [19], detecting 14.9 ± 6% cells with HIV
provirus on day 10, on average (N = 4). HIV RNA was detectable in both models at the time of
RNA-Seq analysis, and increased following treatments that are used to reactivate HIV out of
latency [19, 21]. In addition, a small percentage of cells generated by each of the models, with-
out any reactivation stimuli, is p24+ (average 1.5 ± 1.2 percent and 1.8 ± 1.3 percent for
bystander and cultured TCM models, respectively, N = 4). A diagram in Fig 1 shows a side-by-
side comparison of the key events during the establishment of each model.
To identify genes dysregulated in latency, both TCM and bystander models were compared
to “mock-infected” cells cultured in parallel. These cells underwent the same exposure to acti-
vation stimuli, spin-infection, crowding and ART treatment (in case of cultured TCM), or
exposure to proliferating cells (in case on bystander model) as their infected counterparts. This
design allowed us to control for exposure of cells to cytokines and chemokines in the co-cul-
ture. Data from the cultured TCM model was analyzed previously [21] identifying a total of 826
differentially expressed genes between mock-infected cells and the cells from the model of
HIV latency. The bystander model was analyzed as part of the present study identifying 618
lncRNA and HIV latency
PLOS ONE | https://doi.org/10.1371/journal.pone.0224879 November 11, 2019 3 / 25
differentially expressed genes. To test the effect of the exposure to the virus on gene expression,
gene expression signatures of latently infected cells were compared with a list of interferon
stimulated genes with known antiviral properties [22]. This analysis identified 11 interferon
stimulated genes (out of 826 total genes) for the cultured TCM model and was described previ-
ously [21]. In the present study, bystander model was assessed in a similar manner, and only
one interferon stimulated gene (APOBEC3H) was differentially expressed out of 618 total
genes. We also found two upregulated DNA sensors [23], NLR family pyrin domain contain-
ing 3 (NLRP3) and pyrin and HIN domain family member 1 (PYHIN1), in cultured TCM
model only. Overall, these evaluations suggest that exposure to virus had minimal effect on
gene expression at the time of the assay, and it may be more pronounced in the cultured TCM
compared to the bystander model.
Identification of lncRNAs dysregulated in the models of HIV latency
Identified differentially expressed genes were annotated as protein coding or non-coding
based on their types (e.g. intergenic, antisense, etc.), in both datasets (Tables 1 and S1). Differ-
entially expressed lncRNAs represented 115 (13.9%) and 147 (23.8%) of all differentially
expressed genes in the cultured TCM and the bystander models, respectively. The majority of
dysregulated lncRNA was up-regulated in both models and originated from intergenic or anti-
sense classes, consistent with genome distribution of different lncRNA types (Fig 2). Intronic
lncRNAs were over-represented among lncRNAs dysregulated in latency (cultured TCM
model: OR = 2.36, p = 0.02; bystander model: OR = 3.85, p<0.01). Differentially expressed
genes and lncRNAs in each of the models of HIV latency were then compared, identifying 92
protein coding genes and 10 lncRNAs that were dysregulated in both models (S1 Fig). All dys-
regulated lncRNA were consistently either up- or down-regulated in both models (Table 2).
Validation of expression of lncRNA by ddPCR
Though an overlapping set of dysregulated lncRNAs was identified using RNA-Seq, the differ-
ence in expression of lncRNAs between the model of latency and mock-infected cells was
Fig 1. Comparison of the time-line of latency establishment between cultured TCM and bystander models. Cells during activation stage are depicted with
darker grey color. Resting cells are presented in light grey. Gradient of color for the cultured TCM model represents gradual return from activation to
quiescence. Major steps during model set-up (such as infection and sorting) are indicated above the time-line.
https://doi.org/10.1371/journal.pone.0224879.g001
lncRNA and HIV latency
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frequently less than the effect size of the RNA-Seq experiment (effect size�1.5 with N = 4 bio-
logical replicates). Small differences in expression were not unexpected because each model of
HIV latency is comprised of the mixture of uninfected and latently infected cells, with latently
infected cells ranging from 8.8% to 44.3% [19, 21] (defined as percentage of cells with HIV pro-
virus). Therefore, we aimed to use a method independent of RNA-Seq to validate expression
of a set of overlapping lncRNAs. DdPCR was chosen for this purpose, because it is the most
sensitive technique for detection of small differences in gene expression. Four lncRNAs, PVT1
oncogene (Ensembl ID ENSG00000249859), RP11-347C18.3 (Ensembl ID
ENSG00000253878), RP11-539L10.2 (Ensembl ID ENSG00000246526) and NEAT1 (Ensembl
ID ENSG00000245532), were selected for validation. Same samples that were sequenced, and
three additional sample pairs for the bystander model were analyzed. Up-regulation of PVT1
and RP11-347C18.3 was confirmed both in the cultured TCM and the bystander models (cul-
tured TCM model: PVT1 average fold change 1.8, p = 0.02; RP11-347C18.3 average fold change
2.95, p = 0.01; bystander model: PVT1 average fold change 1.33, p = 0.02; RP11-347C18.3 aver-
age fold change 2.12, p = 0.0002) (S2 Fig). Down-regulation of RP11-539L10.2 was confirmed
Table 1. Overview of differentially expressed protein coding genes and lncRNAs.
Cultured TCM model Bystander model
Differential expression (gene level)
mRNA
Up 456 310
Down 226 124
lncRNA
Up 75 136
Down 40 11
Pseudogene
Up 19 33
Down 9 4
TR_V gene
Up 1 0
Down 0 0
Total 826 618
Differential expression (lncRNA types)
Antisense
Up 32 48
Down 10 5
LincRNA
Up 31 49
Down 19 3
Intronic
Up 4 15
Down 4 1
Sense-overlapping
Up 1 2
Down 3 0
Unclassified (TEC and proctranscript)
Up 7 22
Down 4 2
Total 115 147
https://doi.org/10.1371/journal.pone.0224879.t001
lncRNA and HIV latency
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in the bystander model (average fold change -1.28, p = 0.046) (S2 Fig). Up-regulation of
NEAT1 was not confirmed in either of the models, neither with the assay that detects both
short and long isoforms (N1+N2), nor the long isoform-specific assay (N2) (S2 Fig).
Neither of the RNA-Seq datasets contained the Ensembl identifier for lncRNA NRON
(ENSG00000253079), possibly because it was not present in the reference files used for map-
ping and counting RNA-Seq reads. Because NRON represents the only lncRNA whose
Fig 2. Overview of differentially expressed lncRNAs in the cultured TCM and the bystander models of HIV latency. (A) Volcano plots showing all lncRNAs (grey
dots). Significantly up-regulated lncRNAs (red dots) and down-regulated lncRNAs (blue dots) are highlighted for both latency models. (B) Heatmaps of differentially
expressed lncRNAs. (C) Number of differentially expressed mRNAs, pseudogenes, TR_V genes, and lncRNAs, and percentages of lncRNAs of different types out of the
total dysregulated lncRNAs.
https://doi.org/10.1371/journal.pone.0224879.g002
Table 2. LncRNAs dysregulated in common between the cultured TCM and the bystander model.
Cultured TCM model Bystander model
ENSEMBL ID Gene Symbol lncRNA type logFC FC FDR logFC FC FDR
ENSG00000173727 CMB9-22P13.1 lincRNA 0.86 1.81 0.0115 0.52 1.43 0.0368
ENSG00000232160 RAP2C-AS1 antisense 0.44 1.35 0.0465 0.72 1.65 0.0021
ENSG00000245532 NEAT1 lincRNA 0.50 1.41 0.0438 0.37 1.30 0.0413
ENSG00000246526 RP11-539L10.2 lincRNA -0.66 0.63 0.0377 -0.67 0.63 0.0031
ENSG00000249859 PVT1 lincRNA 0.37 1.29 0.0030 0.58 1.49 0.0000
ENSG00000253878 RP11-347C18.3 sense_intronic 0.73 1.66 0.0014 1.09 2.12 0.0015
ENSG00000266208 CTD-2267D19.3 antisense 0.41 1.32 0.0470 1.15 2.22 0.0105
ENSG00000267702 RP11-53B2.2 sense_intronic 0.51 1.42 0.0253 0.56 1.48 0.0125
ENSG00000271122 RP11-379H18.1 antisense 0.38 1.30 0.0145 0.37 1.29 0.0107
logFC, log2-transformed fold change of counts per million in the RNA-Seq data; FC, fold change; FDR, false discovery rate-corrected p-value.
https://doi.org/10.1371/journal.pone.0224879.t002
lncRNA and HIV latency
PLOS ONE | https://doi.org/10.1371/journal.pone.0224879 November 11, 2019 6 / 25
function in maintaining HIV in latent state has been demonstrated in a primary T-cell model
system and cell from HIV-infected individuals [8], we measured the expression of NRON
using ddPCR. Despite the previous report of a relatively high expression of this lncRNA in pri-
mary CD4+ T-cells [8], we observed relatively low expression, two orders of magnitude lower
than of the other lncRNAs measured. For the cultured TCM model, there was sufficient amount
of RNA to measure NRON from only three out of four sequenced sample pairs. In these three
donors, NRON was strongly and significantly up-regulated (average fold change 4.2, p = 0.003)
in the model of latency compared to mock-infected cells (S2 Fig). Though in some cases
NRON was up-regulated in the bystander model, up-regulation was modest (average fold
change 1.2 for four donors and 1.1 for 7 donors) and not consistent among the seven replicate
experiments (S2 Fig). Thus, though up-regulation of NRON in latency may be used as valida-
tion of our approach of identifying lncRNAs that function in latency control, the discrepant
results for NRON between the two models are consistent with the idea that route of latency
establishment and cell composition may contribute to the mechanisms by which latency is
regulated.
LncRNAs dysregulated in the models of HIV latency have higher
expression in memory compared to naïve T-cells
Memory cells are considered to be the major reservoir of latent HIV provirus [24–28]. If a host
factor functions to promote HIV latency, its expression would likely be higher in memory
than in TN cells. Indeed, an HIV repressor, Blimp-1 (gene symbol PRDM1) was expressed at
significantly higher levels in TCM than in TN cells [29]. Therefore, to further assess whether
identified lncRNAs likely function in latency control, we measured the expression of PVT1,
RP11-347C18.3, RP11-539L10.2 and NRON in TN and memory cell subsets, including TCM
and TEM cells. Uninfected cells sorted into major phenotypic subsets were used for this experi-
ment. While PVT1 and RP11-347C18.3 were up-regulated and RP11-539L10.2 was down-regu-
lated in latency, expression of all three lncRNAs was significantly higher in TCM and TEM
compared to TN cells (Figs 3 and S3). Specifically, PVT1 expression was on average 3-fold
higher in TCM than TN cells (N = 6, p = 0.0005); and on average 2.8-fold higher in TEM than TN
cells (N = 4, p<0.0001). RP11-347C18.3 expression was on average 2-fold higher in TCM
(N = 6, p<0.0001) or TEM (N = 4, p<0.0001) than TN cells. RP11-539L10.2 expression was on
average 6.6-fold higher in TCM than TN cells (N = 6, p<0.0001); and on average 20-fold higher
in TEM than TN cells (N = 4, p<0.0001). Consistent with its repressive function for HIV,
NRON also had higher expression in TCM and TEM compared to TN cells (Figs 3 and S3) (aver-
age 1.7-fold higher in TCM than TN cells (N = 6, p = 0.002); average 4.1-fold higher in TEM than
TN cells (N = 3, p<0.001)). Because PVT1 and RP11-347C18.3 were up-regulated in latency
and in memory cells, their predicted function would be repression of HIV expression. In con-
trast, because RP11-539L10.2 was down-regulated in latency and had higher expression in
memory cells, it would be predicted to promote HIV expression.
Identification of cellular pathways associated with lncRNAs dysregulated
in the models of HIV latency
We further inferred function of dysregulated lncRNAs in HIV latency using GBA analysis,
which determines correlations between lncRNA and mRNA expression in combination with
enrichment strategies to identify cellular pathways associated with lncRNAs. Among the iden-
tified pathways, some were found in association with dysregulated lncRNA for both the cul-
tured TCM and the bystander models (S4 and S5 Figs). Specifically, Spliceosome, Ribosome,
Proteasome, and Protein export pathways from the Kyoto Encyclopedia of Genes and
lncRNA and HIV latency
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Genomes (KEGG), and Proteasome pathway from Biocarta database were associated with
multiple dysregulated lncRNAs in both models (Fig 4). Of these, proteasome function has
been previously implicated in maintaining HIV in latent state, and proteasome inhibitors were
proposed as LRAs [30, 31]. Among other pathways with proposed roles in HIV latent reservoir
establishment or maintenance, were p53 signaling [21] and mammalian target of rapamycin
(MTOR) [32]. KEGG p53 signaling pathway had many lncRNA associations in both models,
while lncRNA associations with Biocarta p53 pathway was only found for the bystander model
(Fig 4). Fewer lncRNAs were associated to Biocarta MTOR, but for both models of HIV
latency (Fig 4). Proper splicing is important for HIV protein production toward viral replica-
tion, but also toward antigen presentation to the immune system for killing of infected cells.
Therefore, we and others propose that regulation of the spliceosome can critically regulate
Fig 3. Comparison of lncRNA expression in TN and TCM T-cells. Expression of PVT1, RP11-347C18.3, RP11-
539L10.2 and NRON was measured by ddPCR and normalized to expression of the housekeeping gene RPL27. Six
independent experiments were performed using uninfected CD4+ T-cells. Significance was determined using a paired
two-sided t-test for log2 transformed data. Data is presented as individual data points (copy numbers normalized to
RPL27) symbol-coded by donor, mean of all values is shown. Samples were generated using blood from donors who
were different from those who participated in the study that used models of HIV latency. TN, naïve CD4+ T-cells; TCM,
central memory CD4+ T-cells.
https://doi.org/10.1371/journal.pone.0224879.g003
lncRNA and HIV latency
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viral latency through multiple mechanisms [33, 34]. Through down-regulation of singly-
spliced and unspliced messages, the virus can remain in a non-replicative state while being
invisible to the immune system. Favoring certain doubly-spliced messages, specifically those
encoded by Nef, the virus can also down-regulate molecules required for antigen presentation
by the infected cell. Thus, it is plausible to hypothesize that spliceosome pathway may also
have relevance to regulation of HIV latency. In addition, splicing factors that contain serine/
arginine (SR) domains are well known regulators of HIV splicing [35]. Dysregulated lncRNA
were found in association with several genes that encode SR protein mRNAs: SRSF2, SRSF3,
SRSF6, SRSF7 and SRSF10.
Next, we explored the associations between lncRNA expression and expression of individ-
ual members (mRNAs) of pathways implicated in HIV latency. Expression of the individual
genes of the KEGG p53 signaling pathway positively correlated with expression of dysregulated
lncRNAs, while Biocarta MTOR showed mostly negative associations (Fig 5). Both KEGG and
Biocarta proteasome pathway exhibited mostly negative associations (Fig 5). Many mRNAs
with highest number of associations to dysregulated lncRNAs were shared for both protea-
some and MTOR pathways. In contrast, p53 pathway had a cluster of mRNAs commonly asso-
ciated with dysregulated lncRNAs for both the cultured TCM and the bystander models (e.g.
top right on the top panel in Fig 5), while other mRNAs were model-specific (e.g. a cluster of
genes specific for the bystander model of HIV latency at the bottom right on the top panel in
Fig 5). Overall, these data are consistent with a possibility that these pathways are regulated via
multiple lncRNAs, and that control by lncRNA has both shared and unique components of the
same pathway.
Fig 4. Pathways associated with lncRNA dysregulated in latency, identified by the guilt-by-association (GBA) analysis. Expression of lncRNAs dysregulated in
latency (EdgeR’s FDR corrected p-value<0.05) was correlated with expression of all detected mRNAs. A ranked mRNA gene list was constructed for each lncRNA
based on their correlation coefficients and used as input for gene set enrichment analysis (GSEA) with KEGG and Biocarta pathway databases. A lncRNA was
considered significantly associated to a pathway when the GSEA FDR corrected p-value was less than 0.05. Number of lncRNA pathway associations is shown on the X-
axis for the bystander model and Y-axis for cultured TCM model, color-coded with blue shades and indicated by the size of the circle (lighter blue color and larger circle
size correspond to the greater number of associations). Ribosome and spliceosome pathways have the most associations with dysregulated lncRNAs in both models.
Pathways that line up along the X axis were identified for the bystander model dataset only; while pathways that line up along the Y axis were identified for the cultured
TCM model only. Pathways relevant to HIV latency are highlighted by red boxes.
https://doi.org/10.1371/journal.pone.0224879.g004
lncRNA and HIV latency
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PVT1 and RP11-347C18.3 are associated with pathways implicated in
regulation of HIV latency
We further focused our attention on lncRNAs that were dysregulated in both models of latency
and validated by ddPCR, namely PVT1, RP11-347C18.3 and RP11-539L10.2. We aimed to
determine whether these lncRNAs were specifically associated with pathways implicated in
regulation of HIV expression. Of these, PVT1 exhibited the most associations (Fig 6), includ-
ing both KEGG and Biocarta p53 signaling pathway, Biocarta MTOR and proteasome path-
ways, and KEGG spliceosome pathway. Most of these associations were found for the
bystander model and not the cultured TCM model; however, spliceosome, and a number of SR
splicing factors in particular associated with PVT1 for both models (Fig 6). RP11-347C18.3
Fig 5. Associations between dysregulated lncRNAs and the mRNA components of pathways implicated in HIV latency. For each lncRNA that was significantly
associated with a pathway of interest (red boxes in Fig 4), leading edge mRNA genes were identified that drive the pathway enrichment score (GSEA). Next, the
number of lncRNAs associated to pathway-specific mRNAs were plotted (ggplot2 v2.2.1). Number of associations between mRNA and lncRNA is shown on the X-
axis for the bystander model and Y-axis for cultured TCM model, and indicated by the size of the circle (larger circle size corresponds to the greater number of
associations). Color shows the percentage of positively correlated mRNA/lncRNA pairs (dark red is 100% positive correlations; dark blue–no positive correlations;
yellow–equal number of positive and negative correlations).
https://doi.org/10.1371/journal.pone.0224879.g005
lncRNA and HIV latency
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was associated with p53 signaling, both for KEGG and Biocarta pathways, and with the KEGG
spliceosome pathway (S2 Table). RP11-539L10.2 was not associated with any annotated path-
ways implicated in HIV latency (S2 Table). The role of RP11-539L10.2 lncRNAs in regulation
of HIV latency cannot be excluded based on these results, because it may function via control
of a single critical host gene or its protein product, by directly targeting HIV, or via a pathway
that is not annotated in the KEGG or Biocarta database. However, roles for PVT1 and RP11-
347C18.3 are more likely based on identification of multiple HIV latency-related pathways
associated with these lncRNAs.
Treatment with SAHA and RMD results in down-regulation of lncRNAs
dysregulated in the models of HIV latency
Finally, we have assessed how treatment with clinically tested LRAs, histone deacetylase inhibi-
tors (HDACi) SAHA and RMD, affects expression of dysregulated lncRNAs. Samples from
four to six replicates from the bystander model were used for this experiment. PVT1 and
NRON were down-regulated by SAHA and RMD in the bystander model and mock-infected
cells (PVT1: SAHA mock average fold-change -1.78, RMD mock average fold change -3.48,
SAHA model of latency average fold change -2.1, RMD model of latency average fold change
-2.8, p<0.0001; NRON: SAHA mock average fold-change -1.9, RMD mock average fold change
Fig 6. Associations between PVT1 and mRNA components of identified associated KEGG and Biocarta pathways. Output of the guilt-by-association analysis
was filtered for PVT1-specific pathway associations and corresponding leading edge mRNAs (GSEA FDR< 0.05). Next, a matrix with PVT1-specific information on
pathway association, HIV latency model, enrichment score and leading edge mRNAs served as input for Cytoscape visualization (v3.4.0). Associations between
PVT1 and mRNAs in all pathways (FDR corrected p<0.05) are shown. Nodes represent individual mRNAs associated with PVT1 and are color coded by model of
HIV latency: blue, cultured TCM model, green, bystander model, and yellow, common association for both models. Nodes in a shape of a rhombus indicate mRNAs
involved in HIV replication (annotated in the NCBI HIV-1 Interaction Database, HIVintDb). The color of the lines connecting PVT1 to mRNAs indicate correlation
(red, positive; blue, negative). Names of pathways implicated in HIV latency are indicated in red.
https://doi.org/10.1371/journal.pone.0224879.g006
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-2.8, SAHA model of latency average fold change -3.5, RMD model of latency average fold
change -2.8, p<0.001) (Fig 7). RP11-347C18.3 was down-regulated in all conditions except by
SAHA in mock-infected cells (RMD mock average fold change -2.0, p = 0.004; SAHA model of
latency average fold change -1.56, RMD model of latency average fold change -2.7, p<0.0001)
(Fig 7). RP11-539L10.2 was down-regulated in all conditions except by RMD in the bystander
model of HIV latency (SAHA mock average fold-change -3.81, RMD mock average fold
change -3.43, p<0.0001; SAHA model of latency average fold change -2.25, p = 0.002) (S6 Fig).
Overall, these results demonstrate that the effects of SAHA and RMD on expression of selected
lncRNAs appear to be independent from HIV infection. As the primary mechanism of action
of HDACi is chromatin decondensation leading to induction of gene transcription, down-
Fig 7. Down-regulation of PVT1, RP11-347C18.3 and NRON by SAHA and RMD. Mock-infected cells and the
bystander model of HIV latency were treated with SAHA (1 μM), RMD (15 nM) or their solvent DMSO for 24 hours.
Expression of lncRNAs was measured by ddPCR and normalized to expression of the housekeeping gene RPL27. Six
replicate experiments were performed. Significance was determined by implementing repeated measures analysis of
variance (RM ANOVA) with library nlme in R using log2 transformed data. Data is presented as individual data points
(copy numbers normalized to RPL27) symbol-coded by donor, mean of all values is shown. DMSO, dimethyl sulfoxide;
SAHA, suberoylanilide hydroxamic acid; RMD, Romidepsin; ns, not significant (p-value> 0.05).
https://doi.org/10.1371/journal.pone.0224879.g007
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regulation of the tested lncRNAs most likely represents a secondary mechanism of action of
these compounds.
Discussion
The present study aimed to prioritize lncRNAs to be tested as targets for HIV latency reversal.
We used several complementary approaches, including the identification of dysregulated
lncRNAs in primary T-cell models of HIV latency (Figs 2 and S1 and S2 and Tables 1, 2 and
S1), GBA analysis (Figs 4–6 and S4 and S5 and S2 Table), evaluation of lncRNA expression in
major CD4+ T-cell maturation subsets (Figs 3 and S3) and in CD4+ T-cells treated with clini-
cally tested LRAs (Figs 7 and S6).
Among lncRNAs dysregulated in the models of HIV latency, 10 were in common between
the two models (Table 2). In addition, 105 unique lncRNAs were identified for the cultured
TCM model, and 137 for the bystander model (S1 Fig). Same protocols were followed to gener-
ate and analyze RNA-Seq data for both models (please refer to Materials and Methods); thus,
discrepancies in the result caused by differences in experimental and analytical procedures are
expected to be minimal. Therefore, it is likely that the observed differences in the identified
dysregulated lncRNAs were due to biological differences of the two models. Specifically, T-cell
composition and route of latency establishment may contribute to differential dysregulation of
lncRNAs in latency. One observation in favor of this conclusion is that NRON was strongly
up-regulated in the cultured TCM model that establishes latency in activated cells returning to
quiescence, but not in the bystander model that uses direct infection of resting cells (S2 Fig). A
prior study that demonstrated the role of NRON in latency maintenance [8] used a model with
a similar route for latency establishment as our cultured TCM model.
We further focused our evaluation of possible functions of the four lncRNAs that were dys-
regulated in both models of latency and had higher expression levels among the ten lncRNA
identified, namely PVT1, RP347C18.3, RP539L10.2 and NEAT1. Of these, NEAT1 differential
expression was not validated by ddPCR in either model (S2 Fig). The prior studies demon-
strating the role of NEAT1 in HIV RNA nuclear retention during productive HIV replication
was performed using cell lines [6, 7]. Therefore, it is possible that NEAT1 may not function in
the same manner in latently infected primary CD4+ T-cells. Because the effect size with the
number of samples (N = 4) available in our RNA-Seq experiment was�1.5, and the observed
difference for NEAT1 was smaller (1.41-fold in the cultured TCM model and 1.3-fold in the
bystander model, Table 2), NEAT1 might represent one of the false positives detected in our
RNA-Seq study. The remaining three selected lncRNAs were confirmed by ddPCR and evalu-
ated in CD4+ T-cells of naïve and memory phenotypes. All of them exhibited higher expres-
sion in TCM and TEM cells (Figs 3 and S3), which represent the major component of the latent
reservoir. PRDM1, a known HIV repressor whose function was evaluated in primary CD4+ T-
cells, exhibited a similar pattern of expression in TN and TCM subsets [29]. LncRNA NRON,
whose repressive function for HIV expression was previously demonstrated in primary CD4
+ T-cells [8], also had higher expression in TCM and TEM compared to TN cells (Figs 3 and
S3). Therefore, our observation of elevated expression of selected lncRNAs in memory cells is
consistent with their possible function in regulation of HIV expression in latency.
GBA analysis was used to hone into potential functions of dysregulated lncRNAs in HIV
latency control by determining whether they are associated to known pathways implicated in
establishment or maintenance of HIV latency. GBA analysis identified proteasome, spliceo-
some, p53 signaling and MTOR among pathways associated with dysregulated lncRNAs (Figs
4 and S4 and S5). Most of the lncRNAs had negative associations with mRNA members of
these pathways (Fig 5), consistent with a possibility of inhibitory regulation of gene expression
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of these pathways by lncRNA. Some of the mechanisms by which this regulation may occur
include transcriptional interference, promoter inactivation by binding transcription factors,
cytoplasmic retention of transcription factors, and epigenetic silencing [13, 36]. In contrast,
the majority of associations in the p53 signaling pathway were positive (Fig 5). Such positive
regulation may as well occur through chromatin remodeling and interactions with and recruit-
ment of transcriptional activators [13]. In addition, lncRNAs may function by increasing sta-
bility of the mRNAs [37]. Negative [38] as well as positive [39] feedback loops have been
reported between lncRNAs and proteins; however, independent studies of interactions
between the identified lncRNAs and the members of associated pathways at the protein level
would be required to determine whether this may be the case for regulation of HIV latency.
Of the three dysregulated lncRNAs that were validated by ddPCR, PVT1 was found in asso-
ciation with multiple pathways implicated in control of HIV latency (Fig 6). The common
pathway identified for the cultured TCM and the bystander models associated with PVT1 was
spliceosome (Fig 6). Remarkably, PVT1 was associated with a number of mRNAs encoding SR
proteins, in common between the two models (Fig 6). Of these, SRSF2, SRSF6, and SRSF10
have been specifically linked to HIV splicing [40–43]. PVT1 was associated with members of
p53 signaling, MTOR and proteasome pathway in the case of the bystander model only (Fig
6), consistent with the idea that pathways that regulate latency may be, at least in part, depen-
dent on the model. PVT1 was found in association with p53 signaling pathway for both KEGG
and Biocarta databases (Fig 6). The role of p53 signaling in HIV establishment and mainte-
nance was demonstrated previously [21]. One protein member of this pathway, MDM2 Proto
Oncogene (MDM2), was stabilized by PVT1 via its interaction with Enhancer Of Zeste 2 Poly-
comb Repressive Complex 2 Subunit (EZH2) in the setting of hepatocellular carcinoma [44].
Though the precise mechanism of regulation of p53 signaling pathway by PVT1 in different
cell types needs further investigation, the positive regulation of it components was consistent
in our study and the study by Guo and colleagues [44]. In addition, EZH2 itself contributes to
regulation of HIV latency [45]. PVT1 interacted with and stabilized the EZH2 protein product
[44], which could represent a potential mechanism of latency control by PVT1. In addition,
PVT1 was shown to act as a sponge for multiple miRNAs [46–51], suggesting the possibility
for positive regulation of multiple mRNAs in the p53 signaling pathway that represent miRNA
targets. Based on these results, we speculate that PVT1 may function in HIV latency control
via modulating mRNA components of p53 signaling pathway and splicing machinery.
Intriguingly, identified associations of PVT1 to cellular pathways demonstrate possible
links between inferred mechanisms of regulation of gene expression by PVT1 in HIV latency
and other diseases, such as basal cell carcinoma and systemic lupus erythematosus (Fig 6). We
speculate that a subset of dysregulated genes that may be regulated by PVT1 is shared between
these conditions. For example, TCF7L2 (also known as TCF-4) from the basal cell carcinoma
pathway plays a role in HIV latency maintenance [52] and was up-regulated in the bystander
model in our study (S1 Table). For the systemic lupus erythematosus pathway, the majority of
genes linked to PVT1 are histone-coding genes. Epigenetic alterations, histone modifications
in particular, largely contribute to gene expression dysregulation in systemic lupus erythema-
tosus [53]. A number of histone-coding genes were dysregulated at the RNA level in systemic
lupus erythematosus [54] and the cultured TCM model in our study (S1 Table).
Lastly, our study investigated the effects of clinically tested LRAs, SAHA and RMD, on
expression of lncRNAs dysregulated in latency, PVT1, RP11-347C18.3, RP11-539L10.2, and
NRON. SAHA and RMD are HDACi, whose primary mechanism of action is histone hypera-
cetylation which results in chromatin decondensation and elevated gene expression. However,
multiple studies demonstrated that HDACi cause gene down-regulation [55–57], which likely
represents secondary mechanisms of action of these compounds. Our prior investigation of
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these secondary effects on protein coding genes suggested presence of both stimulatory and
inhibitory effects of HDACi with respect to HIV reactivation [19, 58]. All tested lncRNAs,
PVT1, RP11-347C18.3, RP11-539L10.2, and NRON were down-regulated by SAHA and RMD,
independent of the presence of latent infection (Figs 7 and S6). When HIV is present, down-
regulation of PVT1, RP11-347C18.3, and NRON, which were up-regulated in latency, may rep-
resent stimulatory effects. Further down-regulation of RP11-539L10.2 by SAHA, beyond levels
of down-regulation observed in latency compared to mock-infected cells, may represent an
inhibitory effect. Thus, both stimulatory and inhibitory effects of HDACi are likely present
among non-coding genes. The results from this study provide basis for hypothesis building to
identify candidate lncRNAs whose experimental down-regulation (such as via knockdowns)
may be synergistic with HDACi treatment for latency reversal.
One limitation of the present study is the low frequency of latently infected cells in a large
background of uninfected cells for both models of HIV latency (range 8.8% to 44.3% [19, 21]).
This is a common problem for models that use replication-competent wild type HIV virus.
Therefore, we conducted a comparison of dysregulated lncRNAs in two different well charac-
terized models [16–19, 21, 59] to attempt to overcome the limitation introduced by high back-
ground of uninfected cells. Only lncRNAs found dysregulated in both models were analyzed
in more detail. Characterization of single cell transcriptomes using the cultured TCM and
bystander models might be beneficial for identification of a greater number of overlapping
lncRNAs and for validating the role of T-cell maturation state and prior activation in lncRNA
expression signatures of latently infected cells.
The second limitation is a possibility that differential gene expression may result from the
exposure of cells to cytokines and chemokines produced by cells during productive infection,
or due to exposure to the virus in culture. To control for cytokine and chemokine exposure
during T-cell activation, we ensured that the mock-infected cells were treated the same way as
infected cells throughout the culture. We have also searched for interferon stimulated genes
with known antiviral properties [22] and DNA sensors [23] among genes that were differen-
tially expressed in the latency models compared to mock-infected cells. Some such responses
were detected, predominantly in the cultured TCM model. It is also possible that transcriptional
profiles could be influenced by virus via interferon-independent cascades [60, 61]. While a
good control for these effects might be the use of anti-virals during the stages of latency estab-
lishment, or the use of cells exposed to the aldrithiol-2 inactivated virus [62] instead of mock-
infected cells, we were limited by analyzing previously published RNA-Seq datasets that did
not include these controls. Nonetheless, identification of a subset of genes with known roles in
HIV latency supports the potential of this experimental and analytical approach to identify
genes specifically affected during HIV latency and not purely by cytokines or exposure to
virus. Indeed, expression of p21 (gene symbol CDKN1A) was elevated in the cell line model of
latency [63] and in the bystander model in the present study (S1 Table). Its expression nega-
tively correlated with cell-associated HIV RNA and HIV transcriptional activity in HIV-
infected virologically suppressed individuals on cART [64], and its protein product inhibited
transcription from the integrated provirus via inhibition of Cyclin Dependent Kinase 9
(CDK9), a component of positive transcription elongation factor (P-TEFb) [65]. Another
example is PRDM1, up-regulated in both models in the present study (S1 Table), which was
previously shown to be a repressor of basal and Tat-dependent HIV transcription [29]. More-
over, expression of the only lncRNA with demonstrated role in HIV repression in primary
CD4+ T-cells, NRON [8], was also up-regulated in the cultured TCM model in the present
study (S2 Fig). These observations are consistent with the idea that at least a subset of genes
and lncRNAs found dysregulated in latency in the present study has demonstrated roles as
HIV regulators. Ultimately, identified lncRNAs will need to be validated as HIV regulators
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using functional studies (e.g. experimental gene expression knockdowns) using relevant model
systems and cells from HIV-infected individuals ex vivo.
In summary, the present study used gene expression profiling by RNA-Seq in two primary
T-cell models of HIV latency to focus on identification of dysregulated lncRNAs. Despite dif-
ferences in cell composition and route of latency establishment between the models, common
lncRNA signatures associated with latency could be identified. LncRNAs dysregulated in
latency had higher expression in memory cells that represent the major HIV reservoir, as com-
pared to TN cells. We further identified pathways associated with dysregulated lncRNA,
including pathways previously implicated in HIV latency: proteasome, spliceosome, p53 sig-
naling and MTOR. Of the lncRNAs that were dysregulated in common between the two mod-
els, PVT1 had the most associations to these pathways. We have proposed several mechanisms
of action for PVT1 to regulate HIV latency, based on evidence for PVT1 function from pub-
lished literature. Identification of model-specific dysregulated lncRNAs and lncRNA-associ-
ated pathways will facilitate better understanding of the mechanisms by which latency is
established and maintained in different cell types. The role of the identified lncRNAs in HIV
latency and their mechanisms of action warrant further experimental exploration to determine
their suitability as targets for antiviral strategies. Our study facilitates prioritization of lncRNAs
to be tested in this setting.
Materials and methods
Study participants
Primary CD4+ T-cells from HIV seronegative volunteer blood donors were used for this
study. The protocol was approved by the Institutional Review Boards of the University of Cali-
fornia San Diego, and the VA San Diego Healthcare System and abides by the Declaration of
Helsinki principles. All volunteers gave written informed consent to participate in the study.
In vitro models of HIV latency
To identify lncRNAs dysregulated in HIV latency, two primary T-cell models were used [16–
18]. In the cultured TCM model, TN cells are activated and polarized to direct differentiation
into TCM cells, which are phenotypically very similar to TCM cells freshly isolated from blood
[17]. Latency is established in the presence of IL-2 and cART in cultured TCM cells that are
gradually returning to quiescence and becoming resting; positive magnetic isolation of CD4
+ T cells is used to sort out cells that remain productively infected [16, 59]. In the bystander
model developed by Dr. Celsa Spina [18, 19], latency is established directly in resting CD4+ T-
cells, represented by all maturation phenotypes found in vivo. Both the cultured TCM and the
bystander models utilized wild type HIVNL4.3 virus. Expression of p24/Gag protein during
model-set up was assessed as described previously, using ICp24 antibody conjugated to fluo-
rescein isothiocyanate (FITC) (clone KC57, Coulter) for cultured TCM model [16]; for
bystander model, ICp24 antibody conjugated to phycoerythrin (PE) (clone KC57, Coulter)
was used. To establish a mock-infected control, a portion of cells was cultured under the same
conditions in parallel, but without exposure to the virus.
Identification of lncRNAs dysregulated in HIV latency
For the cultured TCM model, we used a previously published dataset [21] (raw and processed
data available at Gene Expression Omnibus (GEO) database, accession number https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81810) to re-analyze focusing on dysregulated
lncRNAs. For the bystander model, we used RNA-Seq data available at GEO under accession
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number GSE114883. This dataset includes samples for mock-infected cells and latency model
treated with HDACi SAHA and RMD and their solvent dimethyl sulfoxide (DMSO). DMSO-
treated samples from this dataset were used to perform differential gene expression analysis
between mock-infected cells and cells from the model of HIV latency. To minimize variation
due to analytical procedures, bystander model data was analyzed in the same manner as previ-
ously published TCM model dataset [21]. Briefly, Tophat [66] was used for mapping to human
genome version hg38 and HTSeq [67] for read counting against the Gencode gene annotation
version 21. Mapping to HIV and synthetic RNA standards from the External RNA Controls
Consortium (ERCC) was performed using Bowtie [68]. Differential expression analysis was
performed using library EdgeR [69] in Bioconductor R and normalization to ERCC spike-ins
with RUVSeq [70]. Genes and lncRNAs with false discovery rate (FDR) corrected p-values less
than 0.05 were considered differentially expressed.
Among total differentially expressed genes in both models, lncRNAs and their types (inter-
genic, intronic, etc.) were determined using Gencode gene annotation version 21 with
Ensembl IDs as unique identifiers. Visualization of differential expression included volcano
plots and heatmaps that were constructed via in-house bioinformatics scripts and based on the
package gplots (v3.0.1) in the R computing environment [71]. Enrichment of lncRNA types in
the lists of dysregulated lncRNAs was evaluated via comparison of ratios with the lncRNA type
distribution of the total pool of lncRNAs in the Gencode database (Fisher’s exact test).
Isolation of TN, TCM, and TEM CD4+ T-cell subsets
All antibodies were obtained from BD Biosciences, Inc. (San Jose, CA, USA). Antibodies for cell
quality control were αCD4 (multiclone SK3 SK4) conjugated to FITC, and αHLA-DR (clone
L243) conjugated to PE. Antibodies for isolation of CD4+ T-cell maturation subsets were
αCD45RA (clone L48) conjugated to phycoerythrin-cyanine dye (PE-Cy7), and αCD62L (clone
DREG-56) conjugated to allophycocyanin (APC). CD4+ T-cells were isolated from whole blood
using negative selection (StemCell Technologies, Inc., Vancouver, Canada). All CD4+ T-cell
samples had>95% purity and<10% expression of activation marker HLA-DR, as assessed
using the Accuri C6 flow cytometer (BD Biosciences, Inc., San Jose, CA, USA). To isolate T-cell
maturation subsets, CD4+ T-cells were stained with αCD45RA and αCD62L antibodies, and
sorted on a MoFlo XDP Cell Sorter (Beckman Coulter, Brea, CA, USA) to obtain TN (CD45RA
+CD62L+), TCM (CD45RA-CD62L+) and TEM (CD45RA-CD62L-) cell populations.
Treatment with SAHA and RMD
Aliquots of SAHA and RMD solubilized in DMSO were provided by Merck Research Labora-
tories, Inc. (Kenilworth, NJ, USA), and Gilead Sciences, Inc. (Foster City, CA, USA), respec-
tively. Mock-infected cells and the bystander model of HIV latency were treated with 1 μM
SAHA, 15 nM RMD or their solvent DMSO for 24 hours.
Isolation of RNA
RNA was isolated from CD4+ T-cells using RNeasy micro kit (Qiagen, Inc., Valencia, CA).
RNA concentrations were assessed using Qubit 2.0 fluorometer (Thermo Fisher Scientific,
Inc., Waltham, MA, USA).
Droplet digital PCR (ddPCR)
Four lncRNA dysregulated in both models of latency were selected for confirmation by
ddPCR. The selection was made based on expression level likely detectable in a single ddPCR
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reaction (number of reads per base in the RNA-Seq experiment >0.1). Reads per base were
calculated by dividing the number of reads mapped to each lncRNA by the average transcript
length as determined by GenomicFeatures library [72] in Bioconductor R. The assays to mea-
sure lncRNA expression were custom designed and purchased from Integrated DNA Technol-
ogies, Inc. (Coralville, IA, USA). The assays were as follows: NEAT1 both short and long
isoforms (N1+N2): forward 5’ TTCATGGACCGTGGTTTG 3’, reverse 5’ 56-FAM/CTGC
AATGCTAGGACTCAC 3’, probe 5’ TTCCTCATG/ZEN/GCGAGCAGATGGAAC/3IABkFQ
3’; NEAT1 long isoform (N2): 5’ forward ACGTGTTGCATGGTTTCT 3’, reverse: 5’
ATGAGGGCAGTTCTCTGT 3’, probe 5’ 56-FAM/AACAGTAGG/ZEN/GAGATGCCTGGGA
GTA/3IABkFQ 3’; PVT1: forward 5’ GAGGGTTGAGATCTCTGTTTAC 3’, reverse 5’ GA
TGCTTCACCAGGAAGAG 3’, probe 5’ 56-FAM/TCTGCCAAC/ZEN/TTCCTTTGGGTCTC
C/3IABkFQ 3’; RP11-347C18.3: forward 5’ AGCTCTCATGTGACCCA 3’, reverse 5’
AATAACCTGGTGAGTTGGC 3’, probe 5’ 56-FAM/ACCTGCAAA/ZEN/TTGTGGGCATTC
ACG/3IABkFQ 3’; RP11-539L10.2: forward 5’ TTTGGTCCCTGGCTTTG 3’, reverse 5’
CCCTATCTCTGATCATTGTCAC 3’, probe 5’ 56-FAM/TTGTGACCC/ZEN/GAGTGTCAG
TTTCCT/3IABkFQ/ 3’. NRON lncRNA, which was not annotated in the RNA-Seq data-
sets, was measured by ddPCR using assay Hs04274937_s1 from Applied Biosystems (now
Thermo Fisher Scientific, Inc., Waltham, MA, USA). Housekeeping gene Ribosomal Protein
L27 (RPL27) was used as a normalizer [55, 58, 73]. The assay (HS03044961_g1) to measure
RPL27 was purchased from Applied Biosystems (now Thermo Fisher Scientific, Inc., Waltham,
MA, USA). RNA was converted to cDNA using qScript (Quanta Bio, Beverly, MA). Concen-
tration of RNA in all cDNA reactions was 1 ng/μl, except for lowly expressed NRON, for which
10 ng/μl was used. DdPCR reactions were set up and run as described previously [58].
LncRNAs whose dysregulation in latency were confirmed (PVT1, RP11-347C18.3, RP11-
539L10.2 and NRON) were further measured in CD4+ T-cell maturation subsets and in CD4
+ T-cells following treatment with SAHA and RMD.
GBA analysis
The GBA analysis to associate lncRNAs with biological pathways was performed as described
previously [14, 74]. Briefly, the GBA pipeline first builds a Spearman’s rank correlation matrix
between the differentially expressed lncRNAs and all expressed mRNAs based on the normal-
ized gene expression values of the samples (counts per million). Next, a ranked mRNA gene
list was constructed for each lncRNA based on their correlation coefficients and used as input
for gene set enrichment analysis (GSEA) [75] together with pathways from the Biocarta [76]
and KEGG [77] databases. A lncRNA was considered significantly associated to a pathway
when the GSEA FDR corrected p-value was less than 0.05. The GBA was implemented sepa-
rately for the primary models of HIV latency and results were compared and overlapped after-
wards. Visualization of significant pathway- and mRNA-associations was performed with in-
house R scripts based on the ggplot2 package (v2.2.1). Visualization of individual lncRNA asso-
ciations was performed using Cytoscape v3.4.0 [78].
Statistical analyses
All statistical analyses were performed in the R computing environment [71]. Effect size in the
RNA-Seq experiment was determined using library RNASeqPower [79]. DdPCR data was
expressed as copies of each lncRNA per one thousand copies of RPL27. Because of lower
expression of NRON, this lncRNA was expressed as copies per hundred thousand copies of
RPL27. These normalized copies were log2 transformed. The equal variance test was performed
using function var.test. Based on these results, paired t-tests (function t.test) with equal or
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unequal variance were used for two-group comparisons. For ddPCR validation experiments,
we had prior knowledge about the direction of change of expression in models of latency as
compared to mock-infected cells; therefore, one-sided tests were performed. For two-group
comparisons without prior knowledge of the direction of change, two-sided tests were con-
ducted. Repeated measures analysis of variance (RM ANOVA) was implemented for multi-
group comparisons using library nlme [80] followed by post-hoc Tukey test. For each model,
residuals were measured and tested for normality using the shapiro.test in R. Examination of
the distribution of residuals and ggplots indicated that there were no large deviations from
normality; therefore the requirements of the t-test and ANOVA were satisfied. All graphs were
constructed using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). If RNA
from the same donor was used for multiple measurements, the symbol for that donor is consis-
tently shaped and colored throughout.
Supporting information
S1 Fig. Comparison of dysregulated protein coding genes and lncRNAs in the cultured
TCM and the bystander latency models. Venn diagram was constructed using library Venn-
Diagram v1.16.18 in the R computing environment. Dysregulated lncRNA and protein coding
genes from S1 Table served as input for construction of the Venn diagram. Area of the diagram
is proportional to the number of differentially expressed lncRNAs or protein coding genes.
(PDF)
S2 Fig. Validation of lncRNA dysregulation in latency by ddPCR. Same samples that were
sequenced (cultured TCM model, N = 4) and three additional bystander model samples
(bystander model, N = 7) were subjected to ddPCR with assays to detect selected lncRNA.
Expression of PVT1, RP11-347C18.3, RP11-539L10.2, NEAT1 and NRON was measured by
ddPCR and normalized to expression of the housekeeping gene RPL27. Significance for
ddPCR results was determined using a paired one-sided t-test for log2 transformed data. Data
is presented as individual data points (copy numbers normalized to RPL27) symbol-coded by
donor, mean of all values is shown. N1, NEAT1 isoform 1 (short); N2, NEAT1 isoform 2
(long); ns, not significant (p-value > 0.05); (�) represents experiments where for the cultured
TCM model only three out of four sequenced sample pairs had sufficient RNA for testing.
(PDF)
S3 Fig. Comparison of lncRNA expression in TN, TCM, and TEM T-cells. Expression of
PVT1, RP11-347C18.3, RP11-539L10.2 and NRON was measured by ddPCR and normalized
to expression of the housekeeping gene RPL27. Out of six experiments shown in Fig 2, a subset
of replicates had sufficient number of TEM cells to conduct the assays (N = 4 for PVT1, RP11-
347C18.3 and RP11-539L10.2; N = 3 for NRON). Significance was determined by implement-
ing repeated measures analysis of variance (RM ANOVA) with library nlme in R using log2
transformed data. Data is presented as individual data points (copy numbers normalized to
RPL27) symbol-coded by donor, mean of all values is shown. TN, naïve CF4+ T-cells; TCM,
central memory CD4+ T-cells, TEM, effector memory CD4+ T-cells.
(PDF)
S4 Fig. Unique and common KEGG pathways associated with lncRNA dysregulated in
latency for the cultured TCM and the bystander models, identified by the guilt-by-associa-
tion (GBA) analysis. A. Lists of common and unique pathways. B. Venn diagram showing
overlap of pathways between the two models.
(PDF)
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S5 Fig. Unique and common Biocarta pathways associated with lncRNA dysregulated in
latency for the cultured TCM and the bystander models, identified by the guilt-by-associa-
tion (GBA) analysis. A. Lists of common and unique pathways. B. Venn diagram showing
overlap of pathways between the two models.
(PDF)
S6 Fig. Down-regulation of RP11-539L10.2 by SAHA and RMD. Mock-infected cells and
the bystander model of HIV latency were treated with SAHA (1μM) and RMD (15 nM) or
their solvent DMSO for 24 hours. Expression of RP11-539L10.2 was measured by ddPCR and
normalized to expression of the housekeeping gene RPL27. Four replicate experiments were
performed. Significance was determined by implementing repeated measures analysis of vari-
ance (RM ANOVA) with library nlme in R using log2 transformed data. Data is presented as
individual data points (copy numbers normalized to RPL27) symbol-coded by donor, mean of
all values is shown. DMSO, dimethyl sulfoxide; SAHA, suberoylanilide hydroxamic acid;
RMD, Romidepsin; ns, not significant (p-value > 0.05).
(PDF)
S1 Table. Genes and lncRNAs dysregulated in latency. Data is organized in two Excel sheets,
showing genes and lncRNAs dysregulated in the cultured TCM and the bystander models of
HIV latency. Ensembl_ID, Ensembl gene identifier; HGNC_Gene_Symbol, gene symbol
approved by the HUGO gene nomenclature committee (gencode 21); logFC, log2 transformed
fold change of counts per million in the RNA-Seq data; FDR, false discovery rate adjusted p-
value; gene_type, class of gene according to the nomenclature (protein coding, etc.). Data is
sorted by gene_type and then by FDR within each gene type.
(XLSX)
S2 Table. Cellular pathways associated with lncRNAs RP11-347C18.3 and RP11-539L10.2.
Listed are KEGG and Biocarta pathways that were associated (FDR p<0.05) with RP11-
347C18.3 and RP11-539L10.2 in common for the cultured TCM and the bystander models of
HIV latency, and unique pathways found for each model. Pathways implicated in HIV latency
are highlighted red.
(XLSX)
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